menu
    • menu
    [{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Resiquimod","moa":"Toll-like receptor 7 | Toll-like receptor 8||Toll-like receptor 8 | Toll-like receptor 7","graph1":"Oncology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Spirig Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Resiquimod","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spirig Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Spirig Healthcare \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spirig Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Resiquimod","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascendis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Resiquimod","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascendis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Spirig Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Resiquimod","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase II","graph3":"Spirig Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spirig Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spirig Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Bioluminescence Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"Resiquimod","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SURGE Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"SURGE Therapeutics \/ Bioluminescence Ventures","highestDevelopmentStatusID":"7","companyTruncated":"SURGE Therapeutics \/ Bioluminescence Ventures"},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Resiquimod","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Oncology","graph2":"IND Enabling","graph3":"SURGE Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SURGE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"SURGE Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Resiquimod

    Menu

    Resiquimod

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SURGE Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SURGE Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Bioluminescence Ventures

                            Deal Size : $32.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            SURGE Therapeutics Raises $32M Series B Financing to Advance Intraoperative Immunotherapy to Improve Cancer Pa...

                            Details : The funding will be used for the further development of company's intraoperative immunotherapy, SURGERx with resiquimod (STM-416), in patients with recurrent bladder cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 19, 2023

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Bioluminescence Ventures

                            Deal Size : $32.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SURGE Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SURGE Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SURGE Therapeutics Receives FDA Clearance of IND Application to Initiate Phase 1/2a Study of Intraoperative Im...

                            Details : STM-416 (Resiquimod), is a TLR7 and TLR8 agonist which is being invstigated for prevention of recurrence or progression after transurethral resection of bladder tumor (TURBT) in patients with non-muscle invasive bladder cancer (NMIBC)

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 04, 2023

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ascendis Pharma

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ascendis Pharma

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Escalation Data From TranscendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist i...

                            Details : TransCon TLR7/8 Agonist is an investigational long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (TLR) 7 and 8 designed to provide sustained activation of intratumoral antigen-presenting cells driving tumor antigen present...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 11, 2022

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ascendis Pharma

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ascendis Pharma

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14

                            Details : Resiquimod, a small molecule agonist of Toll-like receptors, is designed to provide sustained activation of intratumoral antigen presenting cells driving tumor antigen presentation and induction of immune stimulatory cytokines in the tumor.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 07, 2021

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Galderma

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Galderma

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

                            Details : CD11301 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, T-Cell, Cutaneous.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 25, 2017

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Spirig Healthcare

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Spirig Healthcare

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma

                            Details : Resiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Basal Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 11, 2013

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Spirig Healthcare

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Spirig Healthcare

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions

                            Details : Resiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratosis, Actinic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 24, 2012

                            Lead Product(s) : Resiquimod

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth